QA/AI & ML Compliance Services

Where Quality Governance Meets Digital Compliance

Person typing on laptop with overlays for AI and ethics

The rapid evolution of artificial intelligence, automation, and digital systems is reshaping regulated industries. ProPharma's QA/AI & ML Compliance Services bridge the gap between innovation and compliance, providing strategic, technical, and regulatory expertise to help you confidently adopt AI and digital technologies, while maintaining GxP integrity and global regulatory alignment.

Empowering Life Science Organizations to Govern Artificial Intelligence (AI) System Compliance Responsibly in the Digital Era.

Globally integrate compliance with AI, digital technologies, and data-driven systems with confidence, Ensuring compliance, validation, and governance are built into every step of the technology-enabled journey.

Connection

AI Strategy Development, Readiness & Implementation

Adverse event intake icon

AI Validation, GxP Compliance & Governance

Signal management icon

Data Integrity (DI) Compliance Assessments

Pharmacovigilance

Cybersecurity Readiness Audits (GxP Focused)

Business professionals collaborating

ProPharma is Your Partner for AI-Driven Quality and Compliance Excellence, delivering:

Regulatory Expertise: Experience with FDA, EMA, MHRA, PMDA, and Health Canada expectations.

Proven AI & ML Readiness Frameworks: Designed for scalable, compliant adoption.

Cross-Functional Expertise: Blending QA, data science, IT, and regulatory insights.

End-to-End Support: From strategy and validation to governance and audit readiness.

Comprehensive Support Across Your AI & ML Compliance Journey

Quality & Compliance Interconnected services are designed to ensure compliant, validated, and high-performing digital ecosystems

AI Strategy Development, Readiness & Implementation

Strengthening the foundation for AI success through structured readiness, governance, and implementation support that aligns with business and regulatory objectives.

  • Supporting clients on AI adoption and process enhancement
  • Enabling faster, smarter decision-making through integrated data and automation
  • Building internal AI capability and readiness
  • Proactively managing compliance and regulatory expectations
  • AI Readiness & Maturity Assessment
  • Digital Blueprint Development & Implementation
  • High-Impact AI Opportunity Identification
  • AI Partnership & Vendor Selection Support
  • AI Implementation Support (Business Process Optimization, OCM)
  • Governance & Performance Monitoring Frameworks
  • AI Compliance & Validation Plan

AI Validation, GxP Compliance & Governance

Ensure your AI/ML tools and algorithms meet stringent GxP, EMA, and FDA regulatory expectations through structured validation and compliance governance.

  • Validation of AI/ML applications in GxP processes (Manufacturing, QC, Clinical, etc.)
  • Assessment of algorithm training data integrity, bias, and traceability
  • Regulatory alignment verification for AI/ML systems in development and manufacturing
  • Validation Protocols & Reports
  • Algorithm Risk Assessments
  • AI/ML Lifecycle SOPs
  • Compliance Roadmaps for AI Use Cases

Data Integrity (DI) Compliance Assessments

Safeguard data trustworthiness and compliance during your digital transformation. Our DI experts assess, align compliance, and enhance your data integrity practices across systems and operations.

  • End-to-end DI audits for digital systems and applications
  • Evaluation of ALCOA+ principles, system controls, audit trails, backup/recovery
  • Map gaps vs. FDA/EMA DI guidelines and best practices
  • Development of upgrade and remediation strategies
  • Current-State DI Maturity Scorecard
  • Gap Analysis & Risk Matrix
  • Prioritized Remediation Plan
  • Updated DI SOPs
  • Support for Remediation Execution

Cybersecurity Readiness Audits (GxP Focused)

Identify and mitigate cybersecurity risks in GxP-critical digital systems to protect data integrity, ensure operational continuity, and align with global regulatory expectations.

  • Assessment of GxP digital systems (eQMS, eTMF, LIMS, MES, SCADA)
  • Evaluation of vulnerabilities and data protection measures
  • Cybersecurity Audit Report
  • GxP-Specific Cyber Risk Remediation Plan
AdobeStock_392700489

Preparing Your Organization for AI Compliance 

Successful AI adoption requires both a strong compliance strategy and a well-informed team. Complement your AI/ML quality and compliance initiatives with specialized training through ProPharma's Validation Center, including the AI in GxP Validation and Compliance course designed to help professionals navigate evolving regulatory expectations and industry best practices. 

QA/AI & ML Compliance Services

Partner with us for expert digital compliance and quality solutions. Contact ProPharma today to learn how we can support your organization’s Artificial Intelligence governance and Quality Assurance needs.

News & Insights

A Risk-Based Road Map for Implementing AI

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Five Metrics That Predict CRO Success (and How to Measure Them)

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determination Means for Manufacturers

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

News & Insights

A Risk-Based Road Map for Implementing AI

June 22, 2026

A Risk-Based Road Map for Implementing AI

Discover a risk-based approach to implementing AI in life sciences, ensuring compliance, transparency, and governance throughout the entire lifecycle.

Five Metrics That Predict CRO Success (and How to Measure Them)

June 15, 2026

Five Metrics That Predict CRO Success (and How to Measure Them)

Discover five key metrics to evaluate CRO success, ensuring timely clinical trials and data integrity while minimizing costs. Learn how to measure them effectively.

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determination Means for Manufacturers

June 10, 2026

FDA Adds Bemotrizinol to OTC Sunscreen Monograph: What the New GRASE Determinati...

Learn how bemotrizinol achieved GRASE status and what FDA's final order adding the ingredient to the OTC sunscreen monograph means for manufacturers and product development.

Previous Post Arrow Next Post Arrow
ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and HTA Capabilities

June 18, 2026

ProPharma Welcomes Kevin van Dooren to Strengthen Integrated EU Regulatory and H...

ProPharma welcomes Kevin van Dooren as Vice President, HEOR and Market Access, strengthening integrated EU regulatory, HTA, reimbursement, and market access capabilities for life sciences companies.

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

May 27, 2026

ProPharma Appoints Adrian Pencak as Chief Commercial Officer

ProPharma announces Adrian Pencak as Chief Commercial Officer, bringing 25 years of leadership experience to enhance global commercial capabilities and client partnerships.

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero Targets

January 27, 2026

ProPharma Sets the Gold Standard in Sustainability with SBTi-Approved Net-Zero T...

ProPharma’s greenhouse gas reduction targets are validated by SBTi, aligning with the Net-Zero Standard and a commitment to reach net-zero by 2050.

Previous Post Arrow Next Post Arrow
ProPharma Recognized for AI Excellence at ECCCSA

January 31, 2025

ProPharma Recognized for AI Excellence at ECCCSA

ProPharma wins Silver at ECCCSA for AI innovation in Medical Information, enhancing efficiency and quality in delivering accurate medical information.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

Previous Award Arrow Next Award Arrow
Case Study Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sensitive Research - ProPharma

June 17, 2026

Meeting Patients Where They Are: Delivering Global Clinical Support for Time-Sen...

Conducting clinical research for rare pediatric populations presents unique operational challenges, particularly when eligible patients may be born anywhere in the world and require immediate...

Case Study Accelerating Commercial Readiness for a Novel Cell Therapy Program - ProPharma

June 10, 2026

Accelerating Commercial Readiness for a Novel Cell Therapy Program

As advanced therapy developers move from research-stage operations toward commercialization, they often face significant challenges in scaling quality systems, aligning regulatory strategy, and...

Case Study Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

May 20, 2026

Keeping Research Moving Under Pressure: Delivering Data Integrity at Speed

When patient enrollment rapidly exceeds expectations, clinical trials can face significant operational strain, putting data integrity, timelines, and critical sponsor decisions at risk. A mid-size...

Previous Resource Arrow Next Resource Arrow
Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

June 2, 2026

Foundations of a Compliant EU–UK GMP–GDP Supply Chain: From Importation to Distribution

A compliant and efficient EU–UK GMP–GDP supply chain requires a clear understanding of roles, responsibilities, and operational integration across importation, certification, and distribution...

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

April 23, 2026

Clinical Promise to Commercial Reality: The Path to Cell & Gene Therapy Market

As cell and gene therapies transition from clinical development to commercialization, organizations face evolving regulatory expectations, expanded CMC requirements, and increased MAH...

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

April 9, 2026

EMA Policy 0070: Advanced Strategies for Compliance, Anonymization, and CCI Justification

As European Medicines Agency Policy 0070 enters its expanded Step 2 phase, sponsors face increased document volumes, heightened transparency obligations, and greater scrutiny of anonymization and CCI...

Previous Webinar Arrow Next Webinar Arrow